Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pregabalin In Partial Seizures (PREPS): An Open-Label, Multicenter Add On Therapy Trial. A Phase IV Open-Label Trial Using 150,300, 600 mg/Day Of Pregabalin

NCT00407797 is registered in ClinicalTrials.gov with Pfizer's Upjohn has merged with Mylan to form Viatris Inc. as lead sponsor.

NCT NCT00407797
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00407797 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pregabalin In Partial Seizures (PREPS): An Open-Label, Multicenter Add On Therapy Trial. A Phase IV Open-Label Trial Using 150,300, 600 mg/Day Of Pregabalin
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase
Phase 4
Overall status
Terminated
Start date
March 31, 2007
Completion date
August 31, 2009
Enrollment
136 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

partial seizures